An improved catalogue for whole-genome sequencing prediction of bedaquiline resistance in Mycobacterium tuberculosis using a reproducible algorithmic approach.

Publication date: Jun 01, 2025

Bedaquiline (BDQ) has only been approved for use for just over a decade and is a key drug for treating multidrug-resistant tuberculosis; however, rising levels of resistance threaten to reduce its effectiveness. Catalogues of mutations associated with resistance to BDQ are key to detecting resistance genetically for either diagnosis or surveillance. At present, building catalogues requires considerable expert knowledge, often requires the use of complex grading rules and is an irreproducible process. We developed an automated method, catomatic, that associates genetic variants with resistance (or susceptibility) using a two-tailed binomial test with a stated background rate and applied it to a dataset of 11,867 Mycobacterium tuberculosis samples with whole-genome and BDQ susceptibility testing data. Using this framework, we investigated how to best classify variants and the phenotypic significance of minor alleles. The genes mmpS5 and mmpL5 are not directly associated with BDQ resistance, and our catalogue of Rv0678, atpE and pepQ variants attains a cross-validated sensitivity and specificity of 79. 4+/-1. 8% and 98. 5+/-0. 3%, respectively, for 94+/-0. 4% of samples. Identifying samples with subpopulations containing Rv0678 variants improves sensitivity, and detection thresholds in bioinformatic pipelines should therefore be lowered. By using a more permissive and deterministic algorithm trained on a sufficient number of resistant samples, we have reproducibly constructed a catalogue of BDQ resistance-associated variants that is comprehensive and accurate.

Open Access PDF

Concepts Keywords
Bioinformatic Algorithms
Decade Antitubercular Agents
Pipelines Antitubercular Agents
Tuberculosis bedaquiline
bedaquiline
Diarylquinolines
Diarylquinolines
Drug Resistance, Bacterial
Genome, Bacterial
Humans
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis
resistance
tuberculosis
Tuberculosis, Multidrug-Resistant
Whole Genome Sequencing
whole-genome sequencing

Semantics

Type Source Name
drug DRUGBANK Bedaquiline
disease MESH multidrug-resistant tuberculosis
disease IDO process
disease IDO susceptibility
disease IDO algorithm
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH Communicable Diseases
disease MESH Infections
drug DRUGBANK D-Proline
drug DRUGBANK Dihydrostreptomycin
disease IDO drug susceptibility
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Gold
drug DRUGBANK Coenzyme M
disease MESH extra pulmonary tuberculosis
drug DRUGBANK Kanamycin
drug DRUGBANK Pretomanid
drug DRUGBANK Linezolid
drug DRUGBANK Moxifloxacin
drug DRUGBANK Rifampicin
drug DRUGBANK Spinosad
drug DRUGBANK ATP
disease IDO production
disease MESH death
drug DRUGBANK Clofazimine
drug DRUGBANK Levofloxacin
drug DRUGBANK Amikacin
drug DRUGBANK Pyrazinamide
pathway REACTOME Metabolism
disease MESH confusion
disease MESH uncertainty

Original Article

(Visited 11 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *